Skip to content
OpenCapital
Get started

NewAmsterdam Pharma Company NAMS Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash

Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies

GATX logo
GATXGATX
$1.75M+243%
CarGurus, Inc. logo
CarGurus, Inc.CARG
-$613K-186%
Seaboard logo
SeaboardSEB
$0-100%
SPS Commerce logo
SPS CommerceSPSC
$288K-56.4%
HTF
Heartflow, Inc. Common StockHTFL
26,200,000%+17,776,022pp
Repligen logo
RepligenRGEN
-$145K-104%

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?
NewAmsterdam Pharma Company (NAMS) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of -$1.33M in Q1 2026.
How has NewAmsterdam Pharma Company's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?
NewAmsterdam Pharma Company's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash decreased by 135.3% year-over-year, from $3.77M to -$1.33M.
What is the long-term trend for NewAmsterdam Pharma Company's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?
Over 3 years (2021 to 2025), NewAmsterdam Pharma Company's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash has grown at a 39.9% compound annual growth rate (CAGR), from -$4.68M to $12.82M.